Terms: = Breast cancer AND DDX3X, DDX14, 1654, ENSG00000215301, DBX, DDX3, HLP2 AND Treatment
18 results:
1. TCTP regulates genotoxic stress and tumorigenicity via intercellular vesicular signaling.
Amson R; Senff-Ribeiro A; Karafin T; Lespagnol A; Honoré J; Baylot V; Banroques J; Tanner NK; Chamond N; Dimitrov JD; Hoebeke J; Droin NM; Job B; Piard J; Bommer UA; Choi KW; Abdelfatah S; Efferth T; Telerman SB; Geyer FC; Reis-Filho J; Telerman A
EMBO Rep; 2024 Apr; 25(4):1962-1986. PubMed ID: 38548973
[TBL] [Abstract] [Full Text] [Related]
2. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway.
Zhang J; Dai H; Huo L; Burks JK; McGrail DJ; Lin SY
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37907220
[TBL] [Abstract] [Full Text] [Related]
3. breast cancer chemotherapy treatment monitoring based on serum sample Raman spectroscopy.
Torre-Gutiérrez LG; Martínez-Zérega BE; Oseguera-Galindo DO; Aguilar-Lemarroy A; Jave-Suárez LF; Torres-González LA; González-Solís JL
Lasers Med Sci; 2022 Dec; 37(9):3649-3659. PubMed ID: 36239879
[TBL] [Abstract] [Full Text] [Related]
4. Molecular docking, synthesis, and biological evaluation of 7-azaindole-derivative (7AID) as novel anti-cancer agent and potent ddx3 inhibitor:-an in silico and in vitro approach.
Doneti R; Pasha A; Botlagunta M; Heena SK; Mutyala VVVP; Pawar SC
Med Oncol; 2022 Sep; 39(11):179. PubMed ID: 36048256
[TBL] [Abstract] [Full Text] [Related]
5. TRIM58 inactivates p53/p21 to promote chemoresistance via ubiquitination of ddx3 in breast cancer.
Wang J; Yang F; Zhuang J; Huo Q; Li J; Xie N
Int J Biochem Cell Biol; 2022 Feb; 143():106140. PubMed ID: 34954155
[TBL] [Abstract] [Full Text] [Related]
6. Psychological well-being and death anxiety among breast cancer survivors during the Covid-19 pandemic: the mediating role of self-compassion.
Yousefi Afrashteh M; Masoumi S
BMC Womens Health; 2021 Nov; 21(1):387. PubMed ID: 34732193
[TBL] [Abstract] [Full Text] [Related]
7. Cytoplasmic ddx3 as prognosticator in male breast cancer.
van der Pol CC; Moelans CB; Manson QF; Batenburg MCT; van der Wall E; Borel Rinkes I; Verkooijen L; Raman V; van Diest PJ
Virchows Arch; 2021 Oct; 479(4):647-655. PubMed ID: 33974127
[TBL] [Abstract] [Full Text] [Related]
8. Targeting mitochondrial translation by inhibiting ddx3: a novel radiosensitization strategy for cancer treatment.
Heerma van Voss MR; Vesuna F; Bol GM; Afzal J; Tantravedi S; Bergman Y; Kammers K; Lehar M; Malek R; Ballew M; Ter Hoeve N; Abou D; Thorek D; Berlinicke C; Yazdankhah M; Sinha D; Le A; Abrahams R; Tran PT; van Diest PJ; Raman V
Oncogene; 2018 Jan; 37(1):63-74. PubMed ID: 28869602
[TBL] [Abstract] [Full Text] [Related]
9. Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy.
Rakovitch E; Nofech-Mozes S; Hanna W; Sutradhar R; Gu S; Fong C; Tuck A; Youngson B; Miller N; Done SJ; Chang MC; Sengupta S; Elavathil L; Jani PA; Bonin M; Lalani N; Paszat L
Breast; 2018 Feb; 37():181-186. PubMed ID: 28781102
[TBL] [Abstract] [Full Text] [Related]
10. Combination treatment using ddx3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
[TBL] [Abstract] [Full Text] [Related]
11. The prognostic effect of ddx3 upregulation in distant breast cancer metastases.
Heerma van Voss MR; Schrijver WA; Ter Hoeve ND; Hoefnagel LD; Manson QF; van der Wall E; Raman V; van Diest PJ;
Clin Exp Metastasis; 2017 Jan; 34(1):85-92. PubMed ID: 27999982
[TBL] [Abstract] [Full Text] [Related]
12. Investigation of conformal and intensity-modulated radiation therapy techniques to determine the absorbed fetal dose in pregnant patients with breast cancer.
Öğretici A; Akbaş U; Köksal C; Bilge H
Med Dosim; 2016; 41(2):95-9. PubMed ID: 26831923
[TBL] [Abstract] [Full Text] [Related]
13. ddx3, a potential target for cancer treatment.
Bol GM; Xie M; Raman V
Mol Cancer; 2015 Nov; 14():188. PubMed ID: 26541825
[TBL] [Abstract] [Full Text] [Related]
14. RNA helicase ddx3: a novel therapeutic target in Ewing sarcoma.
Wilky BA; Kim C; McCarty G; Montgomery EA; Kammers K; DeVine LR; Cole RN; Raman V; Loeb DM
Oncogene; 2016 May; 35(20):2574-83. PubMed ID: 26364611
[TBL] [Abstract] [Full Text] [Related]
15. NZ51, a ring-expanded nucleoside analog, inhibits motility and viability of breast cancer cells by targeting the RNA helicase ddx3.
Xie M; Vesuna F; Botlagunta M; Bol GM; Irving A; Bergman Y; Hosmane RS; Kato Y; Winnard PT; Raman V
Oncotarget; 2015 Oct; 6(30):29901-13. PubMed ID: 26337079
[TBL] [Abstract] [Full Text] [Related]
16. DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked is an immunogenic target of cancer stem cells.
Koshio J; Kagamu H; Nozaki K; Saida Y; Tanaka T; Shoji S; Igarashi N; Miura S; Okajima M; Watanabe S; Yoshizawa H; Narita I
Cancer Immunol Immunother; 2013 Oct; 62(10):1619-28. PubMed ID: 23974721
[TBL] [Abstract] [Full Text] [Related]
17. ddx3 regulates DNA damage-induced apoptosis and p53 stabilization.
Sun M; Zhou T; Jonasch E; Jope RS
Biochim Biophys Acta; 2013 Jun; 1833(6):1489-97. PubMed ID: 23470959
[TBL] [Abstract] [Full Text] [Related]
18. Effect of anti-DR5 and chemotherapy on basal-like breast cancer.
Oliver PG; LoBuglio AF; Zhou T; Forero A; Kim H; Zinn KR; Zhai G; Li Y; Lee CH; Buchsbaum DJ
Breast Cancer Res Treat; 2012 Jun; 133(2):417-26. PubMed ID: 21901385
[TBL] [Abstract] [Full Text] [Related]
